Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in TNBC and BRCA+ Breast Cancer (Window of Opportunity)
NCT02681562Phase 2Unknown
- Sponsor
- ASST Cremona
- Start
- Jan 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of olaparib in triple negative breast cancer (TNBC) and Hereditary Breast Cancer, sponsored by ASST Cremona. Status: unknown.
02
Drugs
olaparib
03
Conditions
triple negative breast cancer (TNBC)Hereditary Breast Cancer
Beyond the preview
Go deeper on NCT02681562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681562.